论文部分内容阅读
有几项研究已证实,在化疗前给急性髓性白血病(AML)病人用GM-CSF可增加进入细胞周期,特别是S期的细胞数,S期细胞最易受到化疗的损伤。故此可使一些病人达到完全缓解(CR)。然而,尚未见有人比较用相似化疗在化疗前用或不用GM-CSF在CR率和存活率方面差别的报道。作者在这个问题上作一些探讨。病人和方法病人接受GM-CSF有两个方案:一为DM-89-124,于1990年1月1日～1990年8月23日施行;二为DM90-062,于1990年8月24日～1990年11月1日施行。
Several studies have demonstrated that GM-CSF administered to patients with acute myeloid leukemia (AML) prior to chemotherapy increases the number of cells entering the cell cycle, especially in S phase, and S phase cells are most vulnerable to chemotherapy. Therefore, some patients can achieve complete remission (CR). However, no one has compared the difference in CR rate and survival with or without GM-CSF with similar chemotherapy before chemotherapy. The author made some discussions on this issue. PATIENTS AND METHODS Patient receiving GM-CSF has two regimens: one is DM-89-124, administered from January 1, 1990 to August 23, 1990; the other is DM90-062, administered on August 24, 1990 ~ November 1, 1990 will come into force.